<DOC>
	<DOC>NCT01814670</DOC>
	<brief_summary>A study to evaluate safety and efficacy of treatment with botulinum toxin Type A (BOTOX®) in Chinese patients with moderate to severe frown lines (Glabellar Rhytides) previously treated with facial laser resurfacing.</brief_summary>
	<brief_title>Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines</brief_title>
	<detailed_description />
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>moderate or severe frown lines facial laser treatment between 4 to 8 weeks prior to Day 1 previous use of botulinum toxin for any indication diagnosis of myasthenia gravis, EatonLambert syndrome, amyotrophic lateral sclerosis microdermabrasion or superficial peels, permanent makeup to the brow and forehead area within the last 3 months facial cosmetic procedures within the last 6 Months treatment to forehead, brow, nose or midface areas with any filler within the last 12 months use of a new topical skin care product within 1 month of the screening any prior forehead or periorbital surgery or brow lift deep dermal scarring, excessively thick sebaceous skin, and/ or loss of skin elasticity any facial skin infection or unhealed skin lesion pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>